The disposition and metabolism of GW695634: A non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS

Xenobiotica

Volumn 40, Issue 6, 2010, Pages 437-445

  De Serres, Mark ^a   Moss, Lee ^a   Sigafoos, James ^a   Sefler, Andrea ^a   Castellino, Stephen ^a   Bowers, Gary ^a   Serabjit Singh, Cosette ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Absorption; AIDS; Amidase; Distribution; Excretion; HIV; Metabolism; NNRTi; Non nucleoside reverse transcriptase inhibitor; Pharmacokinetic; Prodrug; Proteinase

Indexed keywords

AMIDE; CARBON 14; DRUG METABOLITE; GW 678248; GW 695634; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRODRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MONKEY; MOUSE; NONHUMAN; PRODUCT RECOVERY; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; SPECIES COMPARISON;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; BENZOPHENONES; BILE; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS; SULFONAMIDES;

MUS; RATTUS;

EID: 77952259210     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003770578     Document Type: Article

References (16)

1. Becker S, Lelezari J, Walworth C, Kumar P, Cade J, Ng-Cashin J, Kim Y, Scott J, St. Clair M, Jones L, Symonds W. (2006). Antiviral activity and safety of GW695634, a novel next generation NNRTI in NNRTI-resistant HIV-1 infected patients. International Aids Society-Rio. Poster MoPl01.
2. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. (2008). Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 62: 879-888.
3. Cho A. (2006). Recent advances in oral prodrug discovery. Annual Reports in Medicinal Chemistry. Vol. 41: pp. 395-405.
4. Chan J, Freeman G, Tidwell J, Romines K, Schaller l, Cowan J, Gonzales S, Lowell G, Andrews C, Reynolds D, St. Clair M, Hazen R, Ferris R, Creech K, Roberts G, Short S, Weaver K, Koszalka G, Boone L. (2004). Novel benzophenones as nonnucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem 47: 1175-1182.
5. Dieterich DT, Robinson PA, Love J, Stern JO. (2004). Drug-induced liver injury associated with the use of nonnucleoside reversetranscriptase inhibitors. Clin Infect Dis 38 Suppl 2: S80-S89.
6. Ferris RG, Hazen RJ, Roberts GB, St Clair MH, Chan JH, Romines KR, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Weaver KL, Selleseth DW, Moniri KR, Boone LR. (2005). Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 49: 4046-4051.
7. Hazen RJ, Harvey RJ, St Clair MH, Ferris RG, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Romines KR, Chan JH, Boone LR. (2005). Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob Agents Chemother 49: 4465-4473.
8. Kim Y, Symonds W, Steel H, Ng-Cashin J, Moore K. (2004). Safety and pharmacokinetics (PK) of 695634 following repeat oral dose administration to healthy subjects. 44th Interscience Conference on Antimicrobial Agents Chemotherapy. Poster A-23.
9. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, doubleblind, placebo-controlled trial. Lancet 370: 39-48. (Pubitemid 47017467)
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
11. Pauwels R. (2004). New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol 4: 437-446.
12. Pérez-Molina JA. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clin Trials 3: 279-286.
13. Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW 3rd, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR. (2006). Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 49: 727-739.
14. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F. (2005). Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191: 825-829.
15. Sluis-Cremer N, Temiz NA, Bahar I. (2004). Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2: 323-332.
16. Schaller L, Burnette T, Cowan J, Feldman P, Freeman G, Marr H, Owens B, Romines K, Shepard J, Boone L, Chan J. (2003). Abstract. 43rd Interscience Conference on Antimicrobal Agents Chemotherapy. Poster H-872.